SYSTEMATIC REVIEW

Comparison of school based and supplemental vaccination strategies in the delivery of vaccines to 5-19 year olds in Africa - a systematic review [version 1; peer review: 2 approved, 1 approved with reservations]

Eposi C. Haddison¹,², Leila H. Abdullahi¹,³, Rudzani Muloiwa¹,⁴, Gregory D. Hussey¹,³, Benjamin M. Kagina¹,²

¹Vaccines for Africa Initiative (VACFA), University of Cape Town, Cape Town, South Africa
²School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa
³Division of Medical Microbiology & Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
⁴Department of Paediatrics & Child Health, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa

Abstract

Background: Some vaccine preventable diseases (VPDs) still remain a public health burden in many African countries. The occurrence of VPDs in all age groups has led to the realization of the need to extend routine immunisation services to school age children, adolescents and adults. Supplemental immunisation activities (SIAs) and school based vaccinations (SBVs) are common strategies used to complement the expanded programme on immunisation (EPI). This review aimed to assess the effectiveness of SIAs compared to SBVs in the administration of vaccines to 5-19 year olds in Africa.

Methods: Systematic review methods were used to address our study aim. Several electronic databases were searched up to March 30, 2017 for primary studies investigating the delivery of vaccines via SIAs or SBVs to 5-19 year olds. This search was complemented by browsing reference lists of potential studies obtained from search outputs. Outcomes considered for inclusion were: vaccination coverage, costs of the strategy or its effect on routine immunisation services.

Results: Out of the 4938 studies identified, 31 studies met the review inclusion criteria. Both SIAs and SBVs showed high vaccination coverage. However, the SIAs reported higher coverage than SBVs: 91% (95% CI: 84%, 98%) versus 75% (95% CI: 67%, 83%). In most settings, SBVs were reported to be more expensive than SIAs. The SIAs were found to negatively affect routine immunisation services.

Conclusions: Both SIAs and SBVs are routinely used to complement the EPI in the delivery of vaccines in Africa. In settings where school enrolment is suboptimal, as is the case in many African countries, our results show SIAs may be more effective in reaching school age children and adolescents than SBVs. Our results re-iterate the importance of evaluating...
systematic evidence to best inform African authorities on the optimal vaccine delivery strategies targeting school age children and adolescents.

Keywords
Africa, systematic review, school based vaccination, supplemental immunisation activities, adolescents, school age children, routine immunisation

Corresponding author: Eposi C. Haddison (eposihaddison@yahoo.com)

Author roles: Haddison EC: Data Curation, Formal Analysis, Investigation, Methodology, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; Abdullahi LH: Data Curation, Formal Analysis, Methodology, Supervision, Validation, Visualization, Writing – Review & Editing; Muloiwa R: Conceptualization, Methodology, Project Administration, Validation, Visualization, Writing – Review & Editing; Hussey GD: Conceptualization, Methodology, Project Administration, Supervision, Validation, Visualization, Writing – Review & Editing; Kagina BM: Conceptualization, Data Curation, Formal Analysis, Methodology, Project Administration, Supervision, Validation, Visualization, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2017 Haddison EC et al. This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication).

How to cite this article: Haddison EC, Abdullahi LH, Muloiwa R et al. Comparison of school based and supplemental vaccination strategies in the delivery of vaccines to 5-19 year olds in Africa - a systematic review [version 1; peer review: 2 approved, 1 approved with reservations] F1000Research 2017, 6:1833 (https://doi.org/10.12688/f1000research.12804.1)

Introduction
The Expanded Programme on Immunisation (EPI) was founded in 1974 to provide immunisation services to children, both nationally and globally. The EPI has proven to be a cost-effective public health strategy, with reports suggesting that because of the programme, millions of infants’ lives globally have been saved against vaccine preventable diseases (VPDs). Despite the widespread implementation of EPI, some VPDs still remain a public health burden in most of the African countries. Suboptimal vaccination coverage rates in children targeted by the EPI and the inability to expand vaccination services to populations not targeted by the routine immunisation are some of the likely contributors to the high prevalence of VPDs in Africa.

Routinely, school aged children and adolescents are not the primary target of EPI and as a result, an immunisation gap among these age groups has been observed in many settings. To address the immunisation gap, the WHO has recommended the inclusion of several vaccines targeting school aged children and adolescents in national immunisation programmes (NIPs). The WHO recommended vaccines for older children include those against the following pathogens: human papillomavirus (HPV), diphtheria, tetanus, pertussis, measles, rubella, hepatitis B and meningococcus. A majority of the High Income Countries (HICs) have implemented the WHO recommendations of vaccinating the older children, but this is not the case with the Low and Middle Income Countries (LMICs).

Several reasons justify the inclusion of school aged children and adolescents into NIPs. First, infants who miss routine vaccinations remain susceptible to VPDs later in life. Second, immunity acquired through infant immunisation for some VPDs like tetanus and pertussis wanes over time, thus requiring booster doses later in life. Third, there are epidemiological changes of some VPDs like rubella where more infection rates have shifted from infancy to adolescence, thus requiring a review of immunisation policies. Lastly, new vaccines under development such as against HIV and tuberculosis (TB) are likely to target older children and adolescents. In the absence of structured vaccine delivery programs for school age children and adolescents, many settings use school based vaccinations (SBVs) and supplementary immunisation activities (SIAs).

Supplementary immunisation activities, also known as mass vaccination campaigns refer to an immunisation strategy where a large number of people are vaccinated within a defined geographical area and period, regardless of previous vaccination status. The success of SIAs in disease outbreak control as well as in the eradication of smallpox is well documented. However, there are reports suggesting negative effects of SIAs on the routine health services, including EPI.

School based vaccinations (SBVs) target school going children on school premises and within school hours. The SBVs delivery strategy is newer to the EPI compared to SIAs, particularly in Africa. Currently, and in Africa, the main vaccine administered through SBVs is against HPV. Advantages of SBVs include high vaccination coverage and the possibility to extend other health services offered to school age children. However, in Africa, there are millions of children not attending school and are missed by SBVs strategy.

Our study aimed to compare the effectiveness of using SIAs or SBVs to deliver vaccines to 5–19 year olds in Africa.

Methods
This review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Checklist (Supplementary File 1). The protocol was registered with PROSPERO (CRD42017057475).

Search strategy
A search was carried out to identify all relevant studies. Both published and unpublished literatures were searched up to March 30, 2017. No restriction was placed on the publication language. The following electronic databases were searched using both medical subject headings (MeSH) and free text terms relating to vaccination, children, adolescents and Africa (Supplementary Table 1): PubMed, Africa Wide, Cochrane Central Register of Controlled trials (CENTRAL), Cumulative Index to Nursing and Allied Health Literature (CINAHL), World Health Organization Library Information System (WHOLIS), Web of Science, PDQ (Pretty Darn Quick)-Evidence and Scopus. The following grey literature databases were searched for reports, non-peer reviewed and non-indexed papers: WHO, The Global Vaccine Alliance (GAVI) and UNICEF. The reference lists of the included publications were evaluated to identify other potential studies.

Study selection
The following criteria was used to select primary studies for inclusion:

1. the study was either a randomised controlled trial (RCTs), non-RCT, cluster-RCT, interrupted time series, controlled before-and-after, cohort, cross-sectional or case-control;
2. participants were school aged children or adolescents (5–19 years) living in Africa;
3. SIAs or SBVs were the vaccination strategies under investigation;
4. vaccination coverage, cost of vaccine delivery or effects of either strategy (SIAs or SBVs) on routine health services including EPI were reported as any of the outcomes. Retrieved articles were independently screened by two reviewers (HEC and LA). Where study eligibility was unclear, a review was carried out by a third independent study team member (BK).

Data extraction
HEC and LA independently reviewed each included study and extracted data using a piloted data extraction form. Where discrepancies arose HEC, LA and BK reached a consensus by discussion. Corresponding authors were contacted for any missing data needed during the extraction process.
Quality assessment of included studies

Experimental studies were assessed using the Cochrane Collaboration’s tool for assessing risk of bias\textsuperscript{26}, while the Hoy et al., modified tool was used for cross-sectional studies\textsuperscript{27}. Using the Cochrane checklist, studies were scored as ‘High risk’ or ‘Low risk’. Using the Hoy et al., checklist, cross-sectional studies were scored as High risk’ or ‘Moderate risk’ or ‘Low risk’ of bias. Studies with high risk of bias were rated as poor quality while studies with moderate and low risk of bias were rated as moderate and high quality respectively. Where discrepancies in quality assessment occurred, HEC and LA discussed to arrive at a consensus. The quality of studies reporting the cost effectiveness was not assessed since our main interest was only the delivery costs.

Data synthesis and analyses

Data was analysed using Stata v. 14.0. Results from the studies reporting vaccination coverage were expressed as percentages. Reported costs of the delivery strategies were standardised to United States Dollars (USD) if reported in a different currency. The costs of the strategies (SBVs or SIAs) and effects of the strategy on routine vaccination were presented in a narrative form.

A meta-analysis for vaccination coverage using a random effects model with inverse variance proportion was carried out. Pooled statistics for vaccination coverage were expressed as proportions with 95% confidence interval (95% CI). Subgroup analyses were carried to evaluate vaccination coverage per strategy, stratified by study settings or type of vaccine. Missing values were imputed in order to enable a complete case analysis. A sensitivity analysis was then carried out where imputations were done to assess if the results significantly differed due to the data imputations.

Results

Literature search

Three thousand seven hundred and nineteen (3719) studies were identified through searching the electronic databases. A further 1461 were identified from grey literature. An additional five studies were identified from the reference lists of all the search outputs. After duplicates were removed, 4938 studies were left for screening. The titles and abstracts of the 4938 studies were screened and 4872 were not relevant and therefore excluded. The full text of the remaining 65 were retrieved and assessed for eligibility. From the 65 studies, 31 met our inclusion criteria (Supplementary File 2).

Characteristics of included studies

A total of 31 studies were included in this review. There were 20 cross-sectional studies\textsuperscript{23,28–46}, eight economic evaluation studies\textsuperscript{47–54}, one cluster-randomised trial\textsuperscript{55}, one epidemiological report\textsuperscript{56} and one interrupted time series\textsuperscript{57}. The included studies were published between 1993 and 2016; only three studies were published before 2000\textsuperscript{45,46,56}. A total of 17 African countries (Figure 1) and five different vaccines were represented from the included studies. Except for four of the included studies that were written in French\textsuperscript{44,46,50,53}, the rest were in English. One of the study team members (HEC) is French literate and translated the four articles. In terms of vaccine delivery strategy, 20 and 11 studies assessed SIAs and SBVs respectively. Out of these 32 studies, 20 reported on vaccination

Figure 1. Countries and vaccine delivery strategies represented by the 31 included studies.
coverage (Table 1 and Table 2), nine on the cost of the vaccination strategy (Table 3) and three on the effect on routine immunisation (Table 4).

Risk of bias and quality assessment

Using the Hoy et al., modified tool, a 10 item scale was used to assess the internal and external validity of the 20 cross-sectional studies. Ninety-five percent (19) of the studies were of high quality (low risk of bias) meaning further research is unlikely to change our confidence in the estimate of the study outcomes. Five percent (1) of the studies were of moderate quality (moderate risk of bias) meaning further research is likely to have an impact on our confidence in the estimate of the outcomes (Figure 2b). For the internal validity, the included studies defined which participants were considered to have been vaccinated (by self-report or vaccination card) and used the same data collection tool for all the participants. However, five studies did not mention if the tool used was standardised. Ten studies collected information from proxies (parents or guardians of vaccinated children). All the studies calculated vaccination coverage as the ‘number vaccinated divided by the number of the targeted population’. For the external validity, all the studies had representative samples in terms of age and sex. Random sampling was used in all except four studies. Similarly, majority of the studies had a low non-response rate except three studies.

The Cochrane checklist was used to assess the clustered-randomised trial and interrupted time series study (Figure 2a).

Vaccination coverage

SIAs: Twelve studies reported vaccination coverage for SIAs. Three studies reported coverage data on meningococcal serogroup

---

**Table 1. Characteristics of the included studies reporting vaccination coverage for SIAs.**

<table>
<thead>
<tr>
<th>First author and year of publication</th>
<th>Setting</th>
<th>Vaccine</th>
<th>Targeted population</th>
<th>Vaccinated population</th>
<th>Age group of interest</th>
<th>Coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ouatara et al., 2013</td>
<td>Urban/rural</td>
<td>Meningitis (PsA-TT)</td>
<td>817</td>
<td>782</td>
<td>6–15</td>
<td>95.6%</td>
</tr>
<tr>
<td>Meyer et al., 2015</td>
<td>Urban/rural</td>
<td>Meningitis (PsA-TT)</td>
<td>10001</td>
<td>9741</td>
<td>6–15</td>
<td>97.4%</td>
</tr>
<tr>
<td>Tall et al., 2015</td>
<td>Urban</td>
<td>Meningitis (PsA-TT)</td>
<td>232</td>
<td>210</td>
<td>5–19</td>
<td>90.5%</td>
</tr>
<tr>
<td>Luquero et al., 2011</td>
<td>Urban</td>
<td>Measles</td>
<td>-</td>
<td>5–15</td>
<td>95%</td>
<td></td>
</tr>
<tr>
<td>Spiegel et al., 1993</td>
<td>Urban</td>
<td>Meningitis (bivalent A C)</td>
<td>850</td>
<td>833</td>
<td>5–19</td>
<td>98%</td>
</tr>
<tr>
<td>Gil Cuesta et al., 2015</td>
<td>Urban</td>
<td>Measles</td>
<td>-</td>
<td>5–15</td>
<td>87.4%</td>
<td></td>
</tr>
<tr>
<td>Ohuma et al., 2009</td>
<td>Rural</td>
<td>Measles</td>
<td>378</td>
<td>334</td>
<td>5–15</td>
<td>88.3%</td>
</tr>
<tr>
<td>Huhn et al., 2005</td>
<td>Displaced</td>
<td>Yellow Fever (17D)</td>
<td>25230</td>
<td>12238</td>
<td>5–14</td>
<td>48.5%</td>
</tr>
<tr>
<td>Cavailler et al., 2006</td>
<td>Urban</td>
<td>Cholera (rBS-WC)</td>
<td>-</td>
<td>5–14</td>
<td>62.1%</td>
<td></td>
</tr>
<tr>
<td>Bagonza et al., 2013</td>
<td>Rural</td>
<td>Yellow Fever</td>
<td>201</td>
<td>197</td>
<td>5–15</td>
<td>98%</td>
</tr>
<tr>
<td>CDC, 1999</td>
<td>Urban/rural</td>
<td>Measles</td>
<td>4045498</td>
<td>3495415</td>
<td>5–14</td>
<td>86%</td>
</tr>
<tr>
<td>Verguet et al., 2013</td>
<td>Urban/rural</td>
<td>Measles</td>
<td>10383500</td>
<td>7579955</td>
<td>5–14</td>
<td>73%</td>
</tr>
</tbody>
</table>

**Table 2. Characteristics of included studies reporting vaccination coverage for SBV.**

<table>
<thead>
<tr>
<th>First author and year of publication</th>
<th>Setting</th>
<th>Vaccine</th>
<th>Selection criteria</th>
<th>Targeted population</th>
<th>Vaccinated population</th>
<th>Age range</th>
<th>Coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raesima et al., 2015</td>
<td>Urban</td>
<td>HPV</td>
<td>Grade/Age</td>
<td>2488</td>
<td>1967</td>
<td>9–14+</td>
<td>79%</td>
</tr>
<tr>
<td>Binagwaho et al., 2012</td>
<td>Urban/rural</td>
<td>HPV</td>
<td>Grade</td>
<td>94141</td>
<td>88927</td>
<td>12</td>
<td>94.4%</td>
</tr>
<tr>
<td>Moodley et al., 2013</td>
<td>Rural</td>
<td>HPV</td>
<td>Grade/Age</td>
<td>963</td>
<td>938</td>
<td>9–14</td>
<td>97.4%</td>
</tr>
<tr>
<td>Snyman et al., 2015</td>
<td>Rural</td>
<td>HPV</td>
<td>Grade/Age</td>
<td>965</td>
<td>495</td>
<td>9–14</td>
<td>51.2%</td>
</tr>
<tr>
<td>Botha et al., 2015</td>
<td>Urban/rural</td>
<td>HPV</td>
<td>Grade</td>
<td>3465</td>
<td>1859</td>
<td>9–12</td>
<td>53.7%</td>
</tr>
<tr>
<td>Watson-Jones et al., 2012</td>
<td>Urban/rural</td>
<td>HPV</td>
<td>Grade/Age</td>
<td>5532</td>
<td>4211</td>
<td>12–13</td>
<td>76.1%</td>
</tr>
<tr>
<td>La Montagne et al., 2011</td>
<td>Rural</td>
<td>HPV</td>
<td>Grade</td>
<td>2008: 3459</td>
<td>3131</td>
<td>2009: 2835</td>
<td>2512</td>
</tr>
<tr>
<td>Katagwa et al., 2014</td>
<td>Rural</td>
<td>HPV</td>
<td>Age</td>
<td>415</td>
<td>176</td>
<td>9–19</td>
<td>42.4%</td>
</tr>
</tbody>
</table>
Table 3. Characteristics of included studies reporting the cost of the vaccination strategy.

<table>
<thead>
<tr>
<th>First author and year of publication</th>
<th>Setting</th>
<th>Targeted age group (Years)</th>
<th>Vaccine</th>
<th>Vaccinated population</th>
<th>Cost of strategy USD</th>
<th>Cost per fully immunised person</th>
<th>Major sources of expenditure (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>School based vaccinations</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levin <em>et al.</em>, 2013</td>
<td>Rural</td>
<td>Grade 5</td>
<td>HPV</td>
<td>3,038</td>
<td>306,463</td>
<td>9.5</td>
<td>Salaries (40) Start-up costs (27)</td>
</tr>
<tr>
<td><strong>Supplemental immunisation activities</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Verguet <em>et al.</em>, 2013</td>
<td>Urban/Rural</td>
<td>5 – 14</td>
<td>Measles/Polio</td>
<td>12,649,448</td>
<td>36,859,000</td>
<td>2.9</td>
<td>Personnel (58.3) Vaccines (30.6)</td>
</tr>
<tr>
<td>Zengbé-Acray <em>et al.</em>, 2009</td>
<td>Urban</td>
<td>&gt; 6 months</td>
<td>Yellow fever</td>
<td>2,610,994</td>
<td>2,382,582</td>
<td>0.9</td>
<td>Vaccines and consumables (80.6)</td>
</tr>
<tr>
<td>Legros <em>et al.</em>, 1999</td>
<td>Displaced</td>
<td>≥ 1</td>
<td>Cholera</td>
<td>27,607</td>
<td>14,655</td>
<td>0.53</td>
<td>Transport of vaccines (61.8) Consumables (21.8)</td>
</tr>
<tr>
<td>Wallace <em>et al.</em>, 2014</td>
<td>Rural</td>
<td>6 months–15</td>
<td>Measles</td>
<td>457,035</td>
<td>380,052</td>
<td>72.29</td>
<td>Vaccines and consumables (67) Salaries (23)</td>
</tr>
<tr>
<td>da Silva <em>et al.</em>, 2003</td>
<td>Urban/rural</td>
<td>1–25</td>
<td>Yellow fever/ Meningitis A/C</td>
<td>85,925</td>
<td>62,055,44</td>
<td>72.2</td>
<td>Vaccines and consumables (86)</td>
</tr>
<tr>
<td>Uzicanin <em>et al.</em>, 2004</td>
<td>Urban/rural</td>
<td>9 months – 14</td>
<td>Measles</td>
<td>-</td>
<td>Western Cape: 927,287 Mpumalanga: 781,858</td>
<td>0.96</td>
<td>Vaccine administration (73%)</td>
</tr>
<tr>
<td>Schaetti <em>et al.</em>, 2012</td>
<td>Urban/rural</td>
<td>≥ 2</td>
<td>Cholera</td>
<td>23,921</td>
<td>760,000</td>
<td>30</td>
<td>Vaccines (67.1) Salaries of international staff (14.4)</td>
</tr>
</tbody>
</table>

Table 4. Characteristics of included studies reporting effect on routine immunisation.

<table>
<thead>
<tr>
<th>First author and year of publication</th>
<th>Country</th>
<th>Setting</th>
<th>Vaccine</th>
<th>Duration of strategy</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Supplemental immunisation activities</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mounier-Jack <em>et al.</em>, 2014</td>
<td>Mali</td>
<td>Urban/rural</td>
<td>Meningitis (PsA-TT)</td>
<td>10 days</td>
<td>Negative effect. Fewer children vaccinated through routine immunisation during vaccination campaign than expected.</td>
</tr>
<tr>
<td>Verguet <em>et al.</em>, 2013</td>
<td>South Africa</td>
<td>Urban/rural</td>
<td>Measles</td>
<td>3 weeks</td>
<td>Negative effect. The use of child health services decreased during the vaccination campaign</td>
</tr>
<tr>
<td><strong>School based vaccinations</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Torres-Rueda <em>et al.</em>, 2016</td>
<td>Rwanda</td>
<td>Urban/rural</td>
<td>HPV</td>
<td>2 days</td>
<td>No or minimal effect. Routine immunisation continued during the vaccination campaign with the same demand for services.</td>
</tr>
</tbody>
</table>
A (PsA-TT) vaccine\textsuperscript{29,30,44}, five on measles vaccine\textsuperscript{31,32,34,36,57} and two on yellow fever vaccine\textsuperscript{36,43}. Each of the remaining two studies reported on one vaccine; cholera\textsuperscript{38} and meningococcal bivalent polysaccharide A/C vaccine\textsuperscript{46}. Vaccination coverage for SIAs ranged from 48.5\% to 98\% (Table 1).

A meta-analysis of a pooled estimate showed high vaccination coverage for SIAs 86\% (95\% CI: 80\%, 93\%) (Figure 3a). Three studies were excluded from the pooled meta-analysis due to missing sample sizes\textsuperscript{31,32,38}. However, after imputation of the sample sizes based on vaccination coverage, no major difference was seen in the pooled coverage (Figure 3b).

SBVs: Eight studies reported vaccination coverage for SBVs (Table 2). All the SBVs reported coverage of the HPV vaccine among girls aged 9–19 years. Four HPV vaccine studies reported a combination of a grade and age based approach for identifying the target girls for the vaccination\textsuperscript{28,33,40,41}, while three studies reported a grade based only approach\textsuperscript{23,40,41}. The remaining study identified girls for HPV vaccination by age\textsuperscript{42} (Table 2). Vaccination coverage of completed doses among the targeted population ranged from 42.4 – 97.4\%. A meta-analysis of SBVs showed a pooled vaccination coverage of 75\% (95\% CI: 67, 83) (Figure 4).

Comparison of vaccination coverage: To compare the two vaccine delivery strategies, pooled estimates for SIAs and SBVs were evaluated. For this comparison and subsequent analyses, Huhn et al.\textsuperscript{36} was not included since its setting (displaced) is not similar to the other studies reporting SIAs. The SIAs showed a higher vaccination coverage than and SBVs (Figure 5).
Subgroup analyses for vaccination coverage

Subgroup analyses were carried out to evaluate if vaccination coverage varied by the study setting or by vaccine type (for SIAs).

Study setting: The settings evaluated were: urban only, rural and urban mixed, or rural only. For SIAs, vaccination coverage did not vary irrespective of the three study settings (Figure 6). However, vaccination coverage was highest in urban areas (97%, 95% CI: 96, 98) and lowest in a mixed setting (88%, 95% CI: 79, 98).

Similarly for SBVs, there was no variation in vaccination coverage across the three settings. Vaccination coverage in urban, rural and mixed settings were as follows: 79% (95% CI: 77, 81), 74% (95% CI: 63, 85) and 75% (95% CI: 53, 97) respectively.

Vaccine type: There were variations in vaccine coverage dependent on the type of vaccine delivered via SIAs (Figure 7). Of all the vaccinations, measles SIAs reported the lowest coverage 83% (95% CI: 72, 93). Highest vaccination coverage were reported for SIAs
**Figure 4.** Forest plot showing vaccination coverage for SBV.

**Figure 5.** Comparison of vaccination coverage per strategy.
Figure 6. Subgroup analysis of SIA coverage per setting.

<table>
<thead>
<tr>
<th>Study</th>
<th>ES (95% CI)</th>
<th>% Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>URBAN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spiegel 1993</td>
<td>0.98 (0.97, 0.99)</td>
<td>12.60</td>
</tr>
<tr>
<td>Ohuma 2009</td>
<td>0.88 (0.85, 0.91)</td>
<td>12.27</td>
</tr>
<tr>
<td>Subtotal (I² = 9%, p = .)</td>
<td>0.97 (0.96, 0.98)</td>
<td>24.88</td>
</tr>
<tr>
<td>URBAN/RURAL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDC 1999</td>
<td>0.88 (0.86, 0.88)</td>
<td>12.64</td>
</tr>
<tr>
<td>Verguet 2013</td>
<td>0.73 (0.73, 0.73)</td>
<td>12.64</td>
</tr>
<tr>
<td>Custara 2013</td>
<td>0.98 (0.94, 0.97)</td>
<td>12.57</td>
</tr>
<tr>
<td>Meyer 2015</td>
<td>0.97 (0.97, 0.98)</td>
<td>12.63</td>
</tr>
<tr>
<td>Subtotal (I² = 100.00%, p = 0.00)</td>
<td>0.88 (0.79, 0.98)</td>
<td>50.47</td>
</tr>
<tr>
<td>RURAL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bangoza 2013</td>
<td>0.98 (0.96, 0.99)</td>
<td>12.50</td>
</tr>
<tr>
<td>Tall 2015</td>
<td>0.91 (0.86, 0.94)</td>
<td>12.15</td>
</tr>
<tr>
<td>Subtotal (I² = 9%, p = .)</td>
<td>0.96 (0.95, 0.98)</td>
<td>24.65</td>
</tr>
<tr>
<td>Heterogeneity between groups: p = 0.129</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall (I² = 100.00%, p = 0.00),</td>
<td>0.91 (0.84, 0.99)</td>
<td>100.00</td>
</tr>
</tbody>
</table>

Figure 7. Subgroup analysis of SIA coverage per vaccine.

<table>
<thead>
<tr>
<th>Study</th>
<th>ES (95% CI)</th>
<th>% Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>MENINGITIS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spiegel 1995</td>
<td>0.98 (0.97, 0.99)</td>
<td>12.60</td>
</tr>
<tr>
<td>Custara 2013</td>
<td>0.96 (0.94, 0.97)</td>
<td>12.57</td>
</tr>
<tr>
<td>Tall 2015</td>
<td>0.91 (0.86, 0.94)</td>
<td>12.15</td>
</tr>
<tr>
<td>Meyer 2015</td>
<td>0.97 (0.97, 0.98)</td>
<td>12.63</td>
</tr>
<tr>
<td>Subtotal (I² = 84.90%, p = 0.00)</td>
<td>0.96 (0.95, 0.98)</td>
<td>49.95</td>
</tr>
<tr>
<td>MEASLES</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDC 1999</td>
<td>0.86 (0.86, 0.88)</td>
<td>12.64</td>
</tr>
<tr>
<td>Ohuma 2009</td>
<td>0.88 (0.85, 0.91)</td>
<td>12.27</td>
</tr>
<tr>
<td>Verguet 2013</td>
<td>0.73 (0.73, 0.73)</td>
<td>12.64</td>
</tr>
<tr>
<td>Subtotal (I² = 9%, p = .)</td>
<td>0.83 (0.72, 0.93)</td>
<td>37.54</td>
</tr>
<tr>
<td>YELLOW FEVER</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bangoza 2013</td>
<td>0.98 (0.95, 0.99)</td>
<td>12.50</td>
</tr>
</tbody>
</table>

Heterogeneity between groups: p = 0.015
Overall (I² = 100.00%, p = 0.00): 0.91 (0.84, 0.98) 100.00
against meningitis and yellow fever at 96%, (95% CI: 94, 98) and 98% (95% CI: 95, 99) respectively.

Cost of vaccine delivery strategy

SIAs: Seven studies reported the costs of conducting SIAs (Table 3). The costs represent monies spent to deliver the vaccines to the total target population during the SIAs. The available data on costs of the SIAs was not age specific and therefore, the costs for 5–19 year olds only could not be calculated. The SIAs targeted children aged 6 months and older age groups with the number of vaccinated people across all studies ranging from 23,921 to 12,649,448.

Majority of the total cost in SIAs was used to procure vaccines and consumables. The highest proportion (86%) for vaccines and consumables costs was reported by da Silva et al., for the combined yellow fever and meningitis A/C campaign in Senegal. Costs for salaries of health staff and international supervisors were another high expense during SIAs. Other reported minor costs were training of personnel, social mobilisation, transport, maintenance of equipments, cold chain and management of adverse events following immunisation (AEFI).

SBVs: Two studies reported the cost of HPV vaccination in Tanzania and Uganda (Table 3). In Tanzania, 4211 girls were vaccinated with three doses of HPV vaccine either based on age or class. The total economic costs for the SBVs were 349,400 USD. The total cost per fully immunised girl in urban areas were 66 USD and 100 USD for class-based and age-based approach respectively; and in rural areas, 78 USD and 107 USD for class-based and age-based approach respectively. Administration and supervision (salaries) of the project and procurement of vaccines accounted for the major expenses. The reported minor expenses in the study included training, cold chain, waste management and social mobilisation. The observed difference between costs per fully immunised girl for class-based and aged-based selection may be due to the fact that more time and logistics were needed to select girls based on their age. In Uganda, 3038 girls in a rural setting were vaccinated with three doses of HPV vaccine using a class based approach. The total economic cost per fully immunised girl was 9.5 USD. Salaries of staff accounted for the greatest part of the cost followed by micro-planning, staff training, community mobilisation (start-up costs). Other expenses included supplies, cold chain, vehicles and transportation.

Effect of vaccination strategy on routine immunisation

SIAs: Two studies reported the effect of SIAs on routine immunisation and health services. Mounier-Jack et al., reported on a 10 day meningitis A campaign in Mali, in 2010 while Verguet et al., reported on a 3 weeks measles campaign in South Africa in the same year. Both SIAs reported a negative effect on routine immunisation (Table 4).

Low attendance: Both studies reported a decrease in the number of children attending the child clinics during the vaccination period. Mounier-Jack et al., reported a 71–74% decrease in the number of children vaccinated during the campaign while Verguet et al., reported an 8% decrease in the number of children who were weighed in the postnatal clinic.

Redeployment of health staff: During the SIAs, staff in charge of routine immunisations were either deployed as supervisors for the campaign. This led to the closure of routine immunisation services in some districts during the campaign period.

Cold chain management: In Mali, routine vaccines were relocated and stored at the regional and district level so fridges could be made available to store the campaign vaccine.

SBVs: One study in Rwanda reported the effect of HPV vaccination on routine immunisation (Table 4). According to Torres-Rueda et al., the vaccination activity which lasted 2 days had no effect on routine immunisation services. There was no change in the demand for routine immunisation and health services.

Discussion

Both SIAs and SBVs are supplementary EPI programs in many settings, including Africa. Our results show both strategies attain high coverage with SIAs showing greater vaccination coverage than SBVs. However, this coverage should be interpreted with caution since single dose vaccines were administered during the SIAs as opposed to two or three HPV doses during SBVs. Nonetheless, this review showed SIAs negatively affect the provision of routine health services, particularly the EPI. In settings like Africa where many resource challenges prevail, the simultaneous use of both SIAs and SBVs to reach school age and adolescents is questionable.

The high vaccination coverage achieved by SIAs reported in this review corroborates with the past successes of smallpox eradication, achieved by complementing EPI with SIAs. Interestingly, coverage of the SIAs was high irrespective of the vaccine and setting, and this attests to the robustness of the strategy. Despite being a new strategy in Africa and being used for the introduction of HPV vaccines, SBVs was able to achieve a high but variable coverage. Our findings are similar to those obtained in HICs where the SBVs strategy is more established and used for routine immunisation to this age group.

In terms of vaccine coverage, our review supports what is already known: both SIAs and SBVs are good options to complement the EPI. However, other factors such as the costs of the strategy, logistical requirements, the number of vaccine doses to be administered, school attendance and existing immunisation policies have to be taken into consideration when deciding which of the two strategies to use in any given setting. Local evidence should be used to evaluate which vaccine delivery strategy is more optimal to reach school age children and adolescents in Africa.
SBVs are likely to be more cost-effective than SIAs in countries with high school enrolment. Similarly, SBVs are likely to be optimal in countries with strong inter-ministerial collaboration. Collaboration between health and education sectors is crucial to ensure smooth implementation of SBV strategy. Conversely, SBVs are unlikely to be optimal in countries without sufficient financial commitment. School based vaccinations have been reported to be an expensive strategy which may be feasible on a small scale but not sustainable at a national level. Our findings support the reports that SBVs are an expensive strategy although this was based on limited data of newer and more expensive HPV vaccines.

Supplemental immunisation activities, could be the preferred strategy in countries where campaigns are regularly used to complement infant immunisation. The experience in conducting SIAs and community awareness of the strategy can be used to extend the vaccination services to school age children and adolescents. Additionally, the SIAs are able to reach non-school going children. A majority of African countries have millions of non-school going children who will miss vaccines delivered by SBV programs. The negative impacts of SIAs on routine immunisation and health services due to the overlapping of resources (financial and human) is a key concern that should be minimized wherever SIAs are used.

Strengths and limitations
We comprehensively and systematically searched for the relevant literature: both peer-reviewed and non-reviewed records were obtained. This study adhered to the PRISMA guidelines of conducting systematic reviews. Nonetheless, our review had several limitations. First, age specific coverage was not reported in some of the retrieved studies. Second, we observed a high heterogeneity during the meta-analysis. The heterogeneity was likely due to differences across studies of factors such as the age groups included, study settings and period. Third, the only vaccine administered via SBVs was the HPV vaccine, a new and more expensive vaccine. Lastly, few studies reported the effect of SIAs or SBVs on routine immunisation and health services and therefore, our findings may not accurately reflect the effects.

Implication for policy and research
Local evidence is crucial in the review and development of immunisation policies. Both SIAs and SBVs are routinely used in Africa to vaccinate older children. In settings where school enrolment is low as is the case in many African countries, our results show SIAs may be more effective in reaching school age children and adolescents than SBVs. However, caution needs to be exercised to mitigate the negative effect of SIAs on the routine health services. In Africa, the SBV has mainly been tested in the delivery of two or three dose HPV vaccine to adolescent girls while SIAs have been used for diverse vaccines and on a larger scale. Further research is therefore needed to assess the sustainability of SBVs for nationwide delivery of vaccines to school age children and adolescent in resource constraint settings as is the case in Africa. In the event that SBVs are chosen as the main delivery strategy, complementary community activities can be set up to target out of school children. Our results re-iterate the importance of systematic evidence to best inform African authorities on the optimal delivery strategies of vaccines targeted at school age children and adolescents for immunisation.

Data availability
Dataset 1: Characteristics of included studies reporting vaccination coverage. DOI, 10.5256/f1000research.12804.d18061.

Competing interests
No competing interests were disclosed.

Grant information
The author(s) declared that no grants were involved in supporting this work.

Supplementary material
Supplementary File 1: PRISMA Checklist.
Click here to access the data.

Supplementary File 2: PRISMA flowchart, showing the number of records identified, included and excluded.
Click here to access the data.

Supplementary Table 1: Search strategy.
Click here to access the data.


Open Peer Review

Current Peer Review Status: ✓ ✓ ?

Version 1

Reviewer Report 16 January 2018

https://doi.org/10.5256/f1000research.13874.r28617

© 2018 Adetifa I. This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Ifedayo Adetifa
Epidemiology and Demography Department, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya

General Comments
This is a useful article that reviews two essential approaches to the delivery of vaccines in older children/age groups in Africa

Abstract
1. Methods
   1. please list the electronic databases and add a line describing how quality assessment of retrieved articles.
2. Results
   1. Please include number of countries represented by the 32 studies included in the review
3. Conclusions
   1. The authors say, 'Both SIAs and SBVs are routinely used to complement…'. This is incorrect based on the results reported in this review. SIAs are definitely more commonly/routinely used not SBVs.
   2. While the assertion in the 2nd sentence is well known truth, authors have not provided any results in this review to support this.

Introduction
1. 2nd paragraph, 1st sentence- it is not entirely true that the immunisation gap results from the EPI not primarily targeting school aged children and adolescents. Gaps may result from poor coverage of childhood vaccinations, changing epidemiology, waning immunity requiring booster doses, etc. I suggest this paragraph should be revised to highlight the need to find suitable platforms reach older children/adolescents with vaccines primarily targeted at them, to address immunisation gaps and to deliver boosters. This is mentioned in the 3rd paragraph but can come earlier and merged with the 2nd paragraph
2. 3rd paragraph, 4th sentence- The shift in susceptibility to older ages for rubella will be the consequence of introducing rubella vaccine with suboptimal coverage like is currently seen for measles in Africa and as already reported elsewhere. I suggest a revision here to make this clear given the setting for the review.
3. 5th paragraph, 3rd sentence- HPV is not the main vaccine administered through SBVs in Africa. The few pilot HPV SBV do not compare to the use of SBV for MR, YF and MeningA campaigns.

4. 5th paragraph, 4th sentence- is high coverage with SBVs a given considering its dependence on school enrollment? In the few cases where high coverage is reported, is the denominator population all school-age children or just enrolled children?

Methods
1. Study selection, item 2- are school age children/adolescents the same as those enrolled? Should authors not consider differentiating between both or clarify that they mean the same thing for purposes of this review?

2. Study selection, item 4- it is unclear why outcomes around cost of vaccine delivery were not extended to cost effectiveness if the data was reported in retrieved articles. In my opinion, not doing this is a missed opportunity to increase the relevance of results here to policy makers.

3. This will increase the relevance of results here to policy makers.

4. The last sentence under study selection should be started as a new paragraph

5. Quality assessment of included studies- as earlier I mentioned earlier, not including papers reporting cost effectiveness is a significant omission.

6. Data synthesis and analyses-
   1. It is my understanding that a complete case analyses what you do when you restrict analyses to complete datasets followed by imputation for missing values and analyses of datasets with imputed data for comparison? Please clarify
   2. It would be helpful to have some more description of how imputation was done and a summary of the extent of missingness so readers can assess the extent to which the results depend on imputed data.
   3. Why did authors use a 10% significance threshold?
   4. Are the categories of inconsistency arbitrary selections by authors or supported by a reference?

Results
1. Literature search- Most of this text can be left out or shortened since all of this information is displayed in SF2.

2. Characteristics of included study
   1. 1st sentence is a repetition
   2. What is an epidemiological report?
   3. Last sentence page 4, are there 31 or 32 studies?

3. Risk of bias and quality assessment- a table showing the quality rating for each included study would be helpful. Perhaps this table can replace figures 2a and 2b (move to supplementary file) or quality is reported in an additional column in tables 1-4

4. Comparison of vaccination coverage
   1. I think it is more useful to compare the SIA vs SBV for the same vaccines. Coverage for vaccines requiring multiple doses in SIA or SBV should not be compared to those requiring a single dose. There are also other sociocultural and religious issues associated with the uptake of HPV vaccination in particular.
   2. Figure 5 may be more useful if pooled coverage estimates by vaccine are included

5. Subgroup analyses for vaccination coverage
   1. Please revise the 2nd sentence “For SIAs, …”

6. Cost of vaccine delivery strategy
   1. SBVs-Some information about the unit cost of the vaccine would be useful. Also, whether the vaccine procurement was subsidized by GAVI or not.
2. Summaries of the total economic cost per fully immunised child cannot be correct if economic costs do not include vaccine costs.

7. For the pooled coverage estimates, authors do not comment on heterogeneity/I-square results at all yet there is significant heterogeneity for many of the results. Is there an explanation for this?

Discussion
1. 1st paragraph, 2nd sentence- Pooled coverage estimates by vaccine is given in the results so beyond the caveat given for single vs. multiple dose vaccines, it would be useful to read authors’ opinion about the impact of heterogeneity studies in these estimates.

2. 2nd paragraph-
   1. I am not sure I agree measles coverage by SIA should be described as high.
   2. As I alluded to earlier, HPV coverage in SBVs has to be interpreted with caution

3. 4th paragraph- I am not convinced, at least by the results presented here that SBVs are likely to be more cost-effective even with high school enrolment. Authors need to provide more data and vaccine delivery costs are not the same as cost effectiveness of the strategy

4. Strength and limitations
   1. While it is good to see comments about heterogeneity, it is important to mention this in the results according to cut-offs given in the methods.
   2. While school enrolment in general is lower than it should be in Africa, one other limitation is data on school enrolment in the settings covered by included studies was not available

5. Implication for policy and research
   1. I think the conclusion here regarding enrolment and effectiveness of SIAs compared to SBV is speculative. There is simply not enough data in this review especially for SBV to support this.

Are the rationale for, and objectives of, the Systematic Review clearly stated?
Yes

Are sufficient details of the methods and analysis provided to allow replication by others?
Yes

Is the statistical analysis and its interpretation appropriate?
Partly

Are the conclusions drawn adequately supported by the results presented in the review?
Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Paediatrics, infectious diseases, vaccines, epidemiology

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.
Eddy Bresnitz
Merck & Co., Inc., Kenilworth, NJ, USA

Well written report assessing the issue. Methods clearly described. Agree with general comments of the first reviewer. In addition to Dr. Burnett's editorial comments, I have several additional suggestions.

1. On page 4 in the Characteristics section, please clarify whether it's 31 or 32 studies reviewed.

2. In Tables 2 and 3, I suggest the column entitled "Targeted/Vaccinated" be inverted so that the numerator and denominator are in the appropriate relationship in the column.

3. I find that the provision of costs in Table 3 is not really helpful to policy makers. As written, the text just describes facts but does not provide an interpretation of the implications for other programs. Also, I'm not sure comparing SIV programs that use different vaccines, in different countries, is very helpful either. The cost per immunized person is very contextual.

4. Clearly, the SBV programs are limited to HPV whereas the SIV studies are a mélange of vaccines and approached. Perhaps there can be more discussion of how this (and the related social issues) could skew the results.

Are the rationale for, and objectives of, the Systematic Review clearly stated?
Yes

Are sufficient details of the methods and analysis provided to allow replication by others?
Yes

Is the statistical analysis and its interpretation appropriate?
Yes

Are the conclusions drawn adequately supported by the results presented in the review?
Yes

**Competing Interests:** No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
General comments:

This systematic review comparing SIAs to SBVs in Africa has been well designed and conducted, and the conclusions reached are well-founded. The manuscript can however be improved, with some minor editing. This includes deleting the repetition of phrases / words within a sentence / paragraph, as these make some sentences / paragraphs clumsy and increase the word count unnecessarily. Also, abbreviations must (a) only be introduced if they will be used again; (b) be introduced the first time the term is used and used only thereafter; and (c) never reintroduced. An edited version of the PDF has been sent to the supervisor to assist with improving and shortening the manuscript.

Specific comments:

Introduction:

Page 3, paragraph 3: The third point does not adequately explain the issue. The shift in age at infection has occurred because of the introduction of the MMR into the infant vaccination schedule followed by low coverage. Is this a problem in Africa? Surely not, since the MMR is not widely used. The third point here should thus be about vaccines needed before girls become sexually active, and should include both HPV and rubella.

Page 3, paragraph 3, last sentence: School-based vaccinations are offered through structured vaccination delivery programs, but this sentence makes it sound as if they are not.

Page 3, paragraph 5, 2nd sentence: This suggests that in other regions, SBVs preceded SIAs, which is not the case.
Page 3, paragraph 5, 3rd sentence: Reference?

Page 3, paragraph 6: The aim should be unpacked into objectives to clarify exactly what aspects of effectiveness are being measured.

Methods:

Page 3, last part of study selection: The last 2 sentences are not unique to (4), so should start on a new line.

Page 4, end of paragraph 1: Because the objectives have not been clearly stated, the last sentence is not clear.
Results:
In general, what is clearly presented in the tables and figures should not be repeated in the text, as this makes the results section repetitive and too long. Also, be consistent in the way the 95% CI is reported. Conventionally it is xx-xx%, but whichever format is used, use it consistently throughout.

Page 5, 1st sentence under “risk of bias”: This sentence is part of the methods, not the results.
Page 5, end of 3rd sentence in paragraph under risk of bias: Figure 2b is mentioned in the text before Figure 2a.

Page 5, Table 1 and Table 2: The country where the study was conducted should be included in these tables.
Page 6, Table 3: The country where the study was conducted should be included in this table.
Page 6, Table 3: Vergeut et al, column on major expenses: Does the word “Personnel” include more than salaries? If not, then this should be “salaries” to be consistent.

Page 6, Table 3: Legros et al, column on major expenses: Transport is mentioned as a minor cost in the text, but vaccine transport is listed as a major cost here. Or is the transport being referred to in the text, transport of personnel? Clarity is needed.

Page 6, Table 3: Uzicanin et al, column on major expenses: In the text, vaccine administration is summarised as salaries.
Page 6, Table 3: Schaetti et al, column on major expenses: The salary detail for international staff is given here, which immediately raises a question about whether or not staff are local or international in the other studies.
Page 7, Figures 2a and 2b: More details in the captions would add clarity, eg: number of studies, followed by reference numbers.
Page 11 paragraph 2: Can be summarised as personnel salaries being the second major cost driver. Also, transport of vaccines is listed in table 3 in the column on major costs. Or is this transport of personnel?
Page 11 paragraph 3: In the text, vaccine administration is summarised as salaries. See comment about this in table 3. Terms need to be used consistently for clarity.

Page 11, 1st paragraph under SIAs: Very clear in the table, thus unnecessary
Page 11, 1st sentence under “low attendance”: Again, this is clear both from the table and the text below this sentence.
Page 11, 2nd sentence under “redistribution of health staff”: Not stated in the table, and not clear if this was for both studies.

Are the rationale for, and objectives of, the Systematic Review clearly stated?
Partly

Are sufficient details of the methods and analysis provided to allow replication by others?
Yes

Is the statistical analysis and its interpretation appropriate?
Yes
Are the conclusions drawn adequately supported by the results presented in the review?
Yes

**Competing Interests:** No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

---

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com